Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Overland Park, KS, May 27, 2025 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (NASDAQ: DGLY) (the “Company”), today announced that it will host an investor conference call on Wednesday, May 28, 2025, at...
-
Début d’année conforme aux attentes Louvain-la-Neuve, Belgique, le 22 mai 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules, publie...
-
Year starting on track Louvain-la-Neuve, Belgium, 22 May 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the...
-
Quarter Driven by Focus on Deploying Capital into the Refurbished Apple Products Business and Prioritizing Financial Stability for Long-Term Growth First quarter 2025 revenue growth of 25% to $9.9mn...
-
Fort Lauderdale, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME) – an AI technology and consumer electronics holding company, announced today its results...
-
Salt Lake City, Utah, May 15, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading provider of golf simulator software and hardware, announced today its first quarter 2025...
-
Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company...
-
Completed Initial Public Offering (IPO) on February 6, 2025, at $4.00 per Share for Gross Proceeds of Approximately $5.7 Million, Including Partial Exercise of Over-Allotment Option SPRING BRANCH,...
-
LAS VEGAS, May 15, 2025 (GLOBE NEWSWIRE) -- Jet.AI Inc. (the “Company”) (Nasdaq: JTAI), a pure-play artificial intelligence (“AI”) data center company operating aviation-specific AI software, today...
-
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed...